The Effect of Levetiracetam (Keppra) on the Treatment of Tremor in Multiple Sclerosis
|ClinicalTrials.gov Identifier: NCT00430599|
Recruitment Status : Completed
First Posted : February 2, 2007
Last Update Posted : October 12, 2015
|Condition or disease||Phase|
|Multiple Sclerosis||Phase 4|
Multiple Sclerosis is the most common inflammatory demyelinating disease of the CNS and is the leading cause of neurological disability in young adults in the UK (~ 90,000 patients' affected). It has been estimated that the direct cost to the National Health Service is over £300 million/year and the total cost to UK society exceeds £1.3 billion/year. The personal cost in terms of disability is also high with 50% of patients requiring aids to walk or being wheelchair bound within 16 years of disease onset. Recently, attention has focused on disease modifying drugs, including b-Interferon, which have demonstrated a significant reduction in clinical relapse rate associated with a dramatic reduction in disease activity on brain MRI4-7. However, the evidence for any sustained long term benefit is poor. Therefore, symptomatic therapies remain a key part of patient management.
Cerebellar tremor and cerebellar gait instability are present in up to 70% of chronic MS patients and account for a significant amount of clinical morbidity. Cerebellar tremor is a major therapeutic problem in MS since currently there are no effective treatments. To date medical therapies including propranolol, clonazepam, carbamazepine, isoniazid, phenobarbitone, ondansetron, topiramate, gabapentin and cannabis have all been studied with little sustained benefit. More radical surgical treatments including thalamotomy and Deep Brain Stimulation have also been attempted.
However, a recent pilot study, with a small number of patients, suggested that Keppra (Levetiracetam) is effective in treating MS tremor. This study relied upon a rather subjective assessment of tremor and did not assess patients using quantitative physiological measures.
This protocol involves a collaboration between a clinical neurologist, with a recognised expertise in MS, and a research group with an established expertise in the electrophysiological and pharmacological investigation of human tremor11. The protocol describes a study, in MS patients, designed to establish whether Keppra (Levetiracetam) produces:
- Physiologically measurable reduction in tremor;
- Subjective and qualitative reduction in tremor;
|Study Type :||Observational|
|Actual Enrollment :||20 participants|
|Study Start Date :||February 2007|
|Study Completion Date :||September 2009|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00430599
|Sir James Spence Institute, Royal Victoria Infirmary|
|Newcastle, Tyne and Wear, United Kingdom, NE1 4LP|
|Principal Investigator:||Dr P Nichols, MRCP, DPhil||Newcastle NHS Hospitals Trust|